China National Accord Medicines Corp Ltd (200028) — Cash Flow-to-Debt Ratio
China National Accord Medicines Corp Ltd (200028) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of HK$-424.00 Million could theoretically repay 0% of its total liabilities (HK$29.01 Billion) in one year. See 200028 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
China National Accord Medicines Corp Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for China National Accord Medicines Corp Ltd across 28 annual periods. Also explore 200028 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for China National Accord Medicines Corp Ltd (1998–2025)
Year-by-year debt coverage analysis for China National Accord Medicines Corp Ltd. For market capitalisation and broader financial context, see how much is China National Accord Medicines Corp Ltd worth.
| Year | CF-to-Debt Ratio | Operating CF (HKD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | HK$1.64 Billion | HK$27.47 Billion | ▼ -51.1% |
| 2024 | 0.12x | HK$3.27 Billion | HK$26.80 Billion | ▲ +10.5% |
| 2023 | 0.11x | HK$2.94 Billion | HK$26.59 Billion | ▼ 0.0% |
| 2022 | 0.11x | HK$2.56 Billion | HK$23.17 Billion | ▲ +65.3% |
| 2021 | 0.07x | HK$1.66 Billion | HK$24.76 Billion | ▲ +1.0% |
| 2020 | 0.07x | HK$1.50 Billion | HK$22.71 Billion | ▼ -39.9% |
| 2019 | 0.11x | HK$2.00 Billion | HK$18.16 Billion | ▲ +25.1% |
| 2018 | 0.09x | HK$1.32 Billion | HK$15.02 Billion | ▼ -15.0% |
| 2017 | 0.10x | HK$1.29 Billion | HK$12.42 Billion | ▼ -12.8% |
| 2016 | 0.12x | HK$1.47 Billion | HK$12.40 Billion | ▼ -13.3% |
| 2015 | 0.14x | HK$1.05 Billion | HK$7.65 Billion | ▲ +237.1% |
| 2014 | -0.10x | HK$-796.70 Million | HK$7.98 Billion | ▼ -287.7% |
| 2013 | 0.05x | HK$465.03 Million | HK$8.74 Billion | ▲ +22.5% |
| 2012 | 0.04x | HK$323.96 Million | HK$7.46 Billion | ▲ +19.2% |
| 2011 | 0.04x | HK$227.32 Million | HK$6.24 Billion | ▼ -56.0% |
| 2010 | 0.08x | HK$428.16 Million | HK$5.18 Billion | ▲ +33.0% |
| 2009 | 0.06x | HK$270.85 Million | HK$4.36 Billion | ▼ -23.5% |
| 2008 | 0.08x | HK$246.58 Million | HK$3.03 Billion | ▲ +121.3% |
| 2007 | 0.04x | HK$87.70 Million | HK$2.39 Billion | ▼ -55.4% |
| 2006 | 0.08x | HK$181.73 Million | HK$2.21 Billion | ▼ -62.3% |
| 2005 | 0.22x | HK$148.28 Million | HK$678.73 Million | ▼ -18.2% |
| 2004 | 0.27x | HK$130.30 Million | HK$487.99 Million | ▲ +118.8% |
| 2003 | 0.12x | HK$81.22 Million | HK$665.47 Million | ▲ +204.6% |
| 2002 | 0.04x | HK$28.76 Million | HK$717.90 Million | ▼ -57.6% |
| 2001 | 0.09x | HK$71.16 Million | HK$753.72 Million | ▼ -4.9% |
| 2000 | 0.10x | HK$8.52 Million | HK$85.83 Million | ▼ -62.3% |
| 1999 | 0.26x | HK$22.84 Million | HK$86.72 Million | ▲ +477.0% |
| 1998 | 0.05x | HK$5.21 Million | HK$114.11 Million | — |